Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors.
TLR agonist
block copolymer
immunotherapy
nanogel
polymer protein conjugate
vaccine
Journal
ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589
Informations de publication
Date de publication:
22 03 2022
22 03 2022
Historique:
pubmed:
2
2
2022
medline:
19
4
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
The generation of specific humoral and cellular immune responses plays a pivotal role in the development of effective vaccines against tumors. Especially the presence of antigen-specific, cytotoxic T cells influences the outcome of therapeutic cancer vaccinations. Different strategies, ranging from delivering antigen-encoding mRNAs to peptides or full antigens, are accessible but often suffer from insufficient immunogenicity and require immune-boosting adjuvants as well as carrier platforms to ensure stability and adequate retention. Here, we introduce a pH-responsive nanogel platform as a two-component antitumor vaccine that is safe for intravenous application and elicits robust immune responses
Identifiants
pubmed: 35103463
doi: 10.1021/acsnano.1c10709
pmc: PMC8945363
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antigens
0
Cancer Vaccines
0
Nanogels
0
Toll-Like Receptor 7
0
Toll-Like Receptor 8
0
Ovalbumin
9006-59-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4426-4443Références
Small. 2019 Jan;15(4):e1803993
pubmed: 30569516
Nat Nanotechnol. 2019 Sep;14(9):891-901
pubmed: 31384037
Med Microbiol Immunol. 2008 Jun;197(2):145-9
pubmed: 18330599
Bioconjug Chem. 2018 Jul 18;29(7):2394-2405
pubmed: 29889515
Nat Biotechnol. 2015 Nov;33(11):1201-10
pubmed: 26501954
Ther Deliv. 2011 Aug;2(8):1057-77
pubmed: 22826868
Cancer Res. 1998 Aug 15;58(16):3491-4
pubmed: 9721846
Nat Mater. 2019 Feb;18(2):175-185
pubmed: 30643235
Biomaterials. 2018 Sep;178:643-651
pubmed: 29573820
Vaccine. 2008 Mar 20;26(13):1626-37
pubmed: 18295941
Science. 2018 Mar 23;359(6382):1355-1360
pubmed: 29567706
Mol Ther. 2008 Nov;16(11):1833-40
pubmed: 18797453
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
Chem Rev. 2016 Feb 10;116(3):1434-95
pubmed: 26305991
Vaccine. 2010 Nov 23;28(50):7897-906
pubmed: 20934457
Immunology. 2006 Jan;117(1):78-88
pubmed: 16423043
Adv Drug Deliv Rev. 2008 Jun 10;60(9):1018-36
pubmed: 18403044
Nat Biotechnol. 2020 Mar;38(3):320-332
pubmed: 31932728
Immunohorizons. 2018 Jul 2;2(6):185-197
pubmed: 31022686
Adv Mater. 2018 Nov;30(45):e1803397
pubmed: 30276880
J Am Chem Soc. 2004 Nov 24;126(46):15046-7
pubmed: 15547999
Cancer J. 2010 Jul-Aug;16(4):382-91
pubmed: 20693851
ACS Nano. 2019 Oct 22;13(10):10939-10960
pubmed: 31553872
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Angew Chem Int Ed Engl. 2009;48(45):8485-9
pubmed: 19810070
Am J Hematol. 2012 Oct;87(10):953-6
pubmed: 22718533
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
Nanomedicine (Lond). 2016 Oct;11(20):2723-2734
pubmed: 27700619
ACS Nano. 2012 Mar 27;6(3):2198-214
pubmed: 22381078
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7855-60
pubmed: 8755566
Nanomedicine (Lond). 2015;10(20):3147-66
pubmed: 26447353
Infect Immun. 2000 Apr;68(4):1953-63
pubmed: 10722588
J Control Release. 2018 Nov 10;289:125-145
pubmed: 30223044
Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8098-103
pubmed: 27382168
Chem Asian J. 2013 Aug;8(8):1634-44
pubmed: 23606667
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Nat Med. 2013 Apr;19(4):465-72
pubmed: 23455713
Chem Soc Rev. 2012 Mar 21;41(6):2323-43
pubmed: 22170510
Gene Ther. 2011 Jul;18(7):702-8
pubmed: 21368901
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Infect Immun. 1997 May;65(5):1916-25
pubmed: 9125580
J Clin Pharmacol. 2007 Aug;47(8):962-9
pubmed: 17660481
Vaccines (Basel). 2014 Jul 02;2(3):515-36
pubmed: 26344743
Nat Immunol. 2021 Jan;22(1):41-52
pubmed: 33139915
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
NPJ Vaccines. 2019 Feb 8;4:7
pubmed: 30774998
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Expert Rev Clin Pharmacol. 2011 Mar;4(2):275-89
pubmed: 21643519
Macromol Rapid Commun. 2016 Jun;37(11):924-33
pubmed: 27075781
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Immunol Cell Biol. 2003 Apr;81(2):106-13
pubmed: 12631233
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
Angew Chem Int Ed Engl. 2018 Aug 13;57(33):10760-10764
pubmed: 30043442
ACS Nano. 2013 May 28;7(5):3912-25
pubmed: 23590591
J Med Chem. 2017 Mar 9;60(5):2084-2098
pubmed: 28146629
Nat Rev Microbiol. 2007 Jul;5(7):505-17
pubmed: 17558426
Cancer Res. 2018 Jan 15;78(2):463-474
pubmed: 29187401
Biomacromolecules. 2010 Feb 8;11(2):505-14
pubmed: 20050670
Nat Rev Drug Discov. 2007 May;6(5):404-14
pubmed: 17473845
Immunology. 2001 Apr;102(4):486-97
pubmed: 11328383
Ann Oncol. 2017 Dec 1;28(suppl_12):xii44-xii55
pubmed: 28945841
Nat Mater. 2011 Mar;10(3):243-51
pubmed: 21336265
Cancer Res. 2007 May 15;67(10):4996-5002
pubmed: 17510431
Cancer Res. 2001 Feb 1;61(3):1095-9
pubmed: 11221838
Nature. 1989 Nov 30;342(6249):561-4
pubmed: 2586628
Nanomedicine (Lond). 2016 Oct;11(20):2631-2645
pubmed: 27628768